Local pizza restaurant serving up deals for National Pizza Day ahead of Super Bowl
Bruno's Pizza in Port St Joe is going all out offering delicious discounts on their pizza.
The celebrations continue with live music, pizza-eating contests, and fun activities for the whole family.
10th annual memorial poker run raises money for local JROTC scholarships
Employees say pizza plus wings make the perfect Super Bowl meal.
'So we're just having a little event for the community. You know, we got discounted 40% off on our menu prices. $10 buffet and all that stuff we're just here to help the community meaning provide wings and pizza,' General Manager Danny Sayachack said.
Sayacheck says the combination of pizza deals and the big game has made this event even busier than anticipated.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Cowboys' Micah Parsons gets $26.5 million contract update from ESPN's Adam Schefter
Cowboys' Micah Parsons gets $26.5 million contract update from ESPN's Adam Schefter originally appeared on The Sporting News The Dallas Cowboys open the NFL season two weeks from Thursday against the defending Super Bowl champion Philadelphia Eagles. It's still unclear whether Micah Parsons will be on the field, or if his contract negotiations and trade request will lead him elsewhere. On Tuesday, ESPN's Adam Schefter joined The Pat McAfee Show to share what he expects to happen. Here's some of what Schefter had to say: "It feels like they're gonna put up with each other this year. And then, the Cowboys are gonna have the franchise tag and put the franchise tag on him, and then next offseason would be the offseason of the Micah trade. That one, of all the scenarios, feels to be the most logical today." MORE: Meet "Bill," the Commanders' rookie running back gaining acclaim out of nowhere Over The Cap projects the franchise tag for a defensive end next offseason to be worth $26.535 million. That value won't make Parsons happy. He's worth more than $40 million per year on the open market. But if Parsons does indeed play out the 2025 season on the last year of his current deal, the only logical thing for Dallas to do next offseason is give him the franchise tag (assuming they don't agree to a real extension with one another). The Cowboys can't let Parsons get away for free. Using the franchise tag allows them to keep him under their control until potentially finding a trade partner. MORE: Anthony Richardson decision is Colts' latest failure to recover from Andrew Luck Schefter's speculation could create some awkwardness this year, though. If Parsons is truly unhappy but can't land an extension now, his only real choice is to play out the campaign while being a bit ticked off. Cowboys owner Jerry Jones probably wouldn't mind that as long as Parsons is on the field. But if this is really what happens, it likely means the saga in Dallas is a long ways from over. MORE NFL NEWS: Buccaneers reveal new plans for 464-pound rookie Desmond Watson Andrew Luck explains his shock retirement in 5 words Caleb Williams did something vs. Bills that he never did as a rookie Efton Chism III is making his case for the Patriots roster Titans' Elic Ayomanor, Gunnar Helm have potential to shine as rookies The Lions' moment to trade for Trey Hendrickson has arrived
Yahoo
24 minutes ago
- Yahoo
Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial
Merck & Co., Inc. (NYSE:MRK) is included in our list of the . A dose bottle of the medication is in the medical tech's hand On August 12, 2025, Merck & Co., Inc. (NYSE:MRK) announced an update regarding its Phase 3 KEYNOTE-905 trial. According to the update, the trial met its primary and key secondary endpoints in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. The study revealed improved event-free survival, overall survival, and pathologic complete response rates compared to surgery alone. The improved outcome was a result of giving patients KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) medicines before and after surgery. The trial, carried out in collaboration with Pfizer and Astellas, marks the first systemic treatment that enhances survival rates in this patient group. Furthermore, no new side effects were observed. Operating through its Pharmaceutical and Animal Health segments, Merck & Co., Inc. (NYSE:MRK) leads as a healthcare company worldwide. It is included in our list of the most undervalued value stocks to buy. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Oil Refinery Stocks to Buy Right Now and 7 Best Potash Stocks to Buy According to Analysts. Disclosure: None.
Business Wire
4 hours ago
- Business Wire
Cantor Equity Partners IV, Inc. Announces Pricing of $400 Million Initial Public Offering
NEW YORK--(BUSINESS WIRE)--Cantor Equity Partners IV, Inc. (Nasdaq: CEPF) (the 'Company') announced today the pricing of its initial public offering of 40,000,000 Class A ordinary shares at $10.00 per share. The shares are expected to be listed on the Nasdaq Global Market under the symbol 'CEPF' and begin trading on August 21, 2025. The underwriters have been granted a 45-day option to purchase up to an additional 6,000,000 shares offered by the Company to cover over-allotments, if any. The offering is expected to close on August 22, 2025, subject to customary closing conditions. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. About Cantor Equity Partners IV, Inc. Cantor Equity Partners IV, Inc. is a blank check company sponsored by Cantor Fitzgerald and led by Chairman and Chief Executive Officer Brandon Lutnick. Cantor Equity Partners IV, Inc. was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company's efforts to identify a prospective target business will not be limited to a particular industry or geographic region, but the Company intends to focus on a target in an industry where it believes the Company's management teams' and affiliates' expertise will provide the Company with a competitive advantage, including the financial services, digital assets, healthcare, real estate services, technology and software industries. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the 'SEC') on August 20, 2025. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor New York, New York 10022; Email: prospectus@ Copies of the registration statement can be accessed through the SEC's website at This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the successful consummation of the Company's initial public offering and use of the net proceeds of the offering as described in the offering prospectus, are subject to risks and uncertainties including those set forth in the Risk Factors section of the Company's registration statement for the offering filed with the SEC, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
